 CureVac NV NASDAQ: CVAC disclosed among the COVID-19 vaccine highlights that 465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to develop the mRNA cancer vaccine candidate since 2014, when CureVac received about 35 million upfront and nearly 430 million in promised milestones. 